Those findings of greater OR in those subgroups was based in post hoc analysis - which is why the results are seen as hypothesis generating rather than evidence of efficacy.
This is standard, and you should really understand why that distinction is important. If you don't, you likely don't understand enough about the scientific method and should be wary when investing in this field.
The FDA understands this. This is why MSB is having a hard time, and why some of us predicted that. Ask yourself why some here, most who haven't invested in MSB, seem to predict these things? It's not magic, it's just science.
This is from the paper (not an article about the paper), regarding the primary endpoints which the study was designed for.
Ann: Mesoblast Partners with BMT CTN on Adult SR-aGVHD Trial, page-153
-
- There are more pages in this discussion • 210 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |